Xeris Pharmaceuticals   Report issue

For profit Phase 1 Phase 2 Phase 3
Founded: Chicago IL United States (2005)
Status: No NME R&D (2005)

Organization Overview

First Clinical Trial
2013
NCT01972152
First Marketed Drug
2005
diclofenamide
First NDA Approval
None
Last Known Activity
2019

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

XERIS | Xeris Pharmaceuticals

Active Ingredients

Marketed Drugs (2)

diclofenamide (1958)

glucagon (2019)

Drugs in Phase 3 Trials (2)

Key: Xeris Pharmaceuticals (1) Acquired (1)

glucagon (17 trials)

ketoconazole (nizoral) (6 trials)

Drugs in Phase 2 Trials (3)

glucose (2 trials)

insulin human (humulin) (2 trials)

pramlintide (symlin) (1 trial)

Drugs in Phase 1 Trials (1)

Key: Xeris Pharmaceuticals (0) Acquired (1)

metformin (glucophage) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Congenital Hyperinsulinism (Phase 2)

Diabetes Mellitus (Phase 2)

Diabetes Mellitus, Type 1 (Phase 3)

Hyperinsulinism (Phase 2)

Hypoglycemia (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 24
  • # of Trial APIs: 6